<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941128-2-00088</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> The purpose of this analysis is to facilitate public comment on the proposed Order, and it is not intended to constitute an official interpretation of the agreement and proposed Order or to modify in any way their terms. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Donald S. Clark, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Secretary. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> Concurring Statement of Commissioner Mary L. Azcuenaga <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> In  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> American Home Products Corp., <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  File No. 941&hyph;0116 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Today, the Commission accepts for public comment a consent agreement settling charges that American Home Products' proposed acquisition of American Cyanamid Company is likely substantially to lessen competition in the markets for three existing diphtheria and tetanus vaccines and substantially to lessen competition to develop a new rotavirus vaccine and to develop and produce cytokines. This appears to be a strong antitrust case, but I seriously question whether the remedy is sufficient. <!-- PJG 0012 frnewline --> Under the order, the divestiture of tetanus and diphtheria vaccine assets is limited to certain intellectual property, including formulations, patents, trade secrets, technology, and know-how. The divestiture is structured so that, as a practical matter, the only firms that could acquire the assets in question are firms that in my opinion already would satisfy the tests under the law for potential entrants. In short, the order will not restore the competition lost as a result of the acquisition. Instead, the Commission should require the divestiture of a viable business unit, even if that business unit produces and sells products other than the vaccines in question. <!-- PJG /ITAG -->  <!-- PJG QTAG 03 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;29181 Filed 11&hyph;25&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 6750&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            